Correlation between increasing EFS and decreasing overall use of health care per month of OS. Among patients with ELN intermediate-risk AML (A), ELN adverse-risk AML (B), age <65 years (C), age ≥65 years (D), receiving intensive chemotherapy with or without other non-chemotherapy agents (E), and receiving hypomethylating agents with or without other non-chemotherapy agents (F).